Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 1
2018 2
2019 5
2020 6
2021 4
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Stem cells for respiratory failure.
Curley GF, McAuley DF. Curley GF, et al. Curr Opin Crit Care. 2015 Feb;21(1):42-9. doi: 10.1097/MCC.0000000000000171. Curr Opin Crit Care. 2015. PMID: 25486575 Review.
Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cells (REALIST-COVID Trial): A Multicenter, Randomized, Controlled Clinical Trial.
Gorman EA, Rynne J, Gardiner HJ, Rostron AJ, Bannard-Smith J, Bentley AM, Brealey D, Campbell C, Curley G, Clarke M, Dushianthan A, Hopkins P, Jackson C, Kefela K, Krasnodembskaya A, Laffey JG, McDowell C, McFarland M, McFerran J, McGuigan P, Perkins GD, Silversides J, Smythe J, Thompson J, Tunnicliffe WS, Welters IDM, Amado-Rodríguez L, Albaiceta G, Williams B, Shankar-Hari M, McAuley DF, O'Kane CM. Gorman EA, et al. Am J Respir Crit Care Med. 2023 Aug 1;208(3):256-269. doi: 10.1164/rccm.202302-0297OC. Am J Respir Crit Care Med. 2023. PMID: 37154608 Clinical Trial.
Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.
Zumla A, Wang FS, Ippolito G, Petrosillo N, Agrati C, Azhar EI, Chang C, El-Kafrawy SA, Osman M, Zitvogel L, Galle PR, Locatelli F, Gorman E, Cordon-Cardo C, O'Kane C, McAuley D, Maeurer M. Zumla A, et al. Int J Infect Dis. 2020 Jul;96:431-439. doi: 10.1016/j.ijid.2020.05.040. Epub 2020 May 17. Int J Infect Dis. 2020. PMID: 32425638 Free PMC article.
Where next for cell-based therapy in ARDS.
Boyle AJ, O'Kane CM, McAuley DF. Boyle AJ, et al. Thorax. 2019 Jan;74(1):13-15. doi: 10.1136/thoraxjnl-2018-212272. Epub 2018 Nov 12. Thorax. 2019. PMID: 30420408 No abstract available.
Proceedings of the ISCT scientific signature series symposium, "Advances in cell and gene therapies for lung diseases and critical illnesses": International Society for Cell & Gene Therapy, Burlington VT, US, July 16, 2021.
Ting AE, Baker EK, Champagne J, Desai TJ, Dos Santos CC, Heijink IH, Itescu S, Le Blanc K, Matthay MA, McAuley DF, McIntyre L, Mei SHJ, Parekkadan B, Rocco PRM, Sheridan J, Thébaud B, Weiss DJ. Ting AE, et al. Cytotherapy. 2022 Aug;24(8):774-788. doi: 10.1016/j.jcyt.2021.11.007. Epub 2022 May 22. Cytotherapy. 2022. PMID: 35613962 Review.
Emerging pharmacological therapies for ARDS: COVID-19 and beyond.
Horie S, McNicholas B, Rezoagli E, Pham T, Curley G, McAuley D, O'Kane C, Nichol A, Dos Santos C, Rocco PRM, Bellani G, Laffey JG. Horie S, et al. Intensive Care Med. 2020 Dec;46(12):2265-2283. doi: 10.1007/s00134-020-06141-z. Epub 2020 Jul 11. Intensive Care Med. 2020. PMID: 32654006 Free PMC article.
20 results